TAF1L Products

Description

Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene.  The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo.  Chimera RNAi has many advantages over the conventional siRNAs.  First, it has been demonstrated to have reliable knock-down for over 10,000 human genes.  Because the human genome is composed of an intricate, genetic network, chimera RNAi's unique design has successfully obviated the off-target effects including microRNA-based influence.  Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected.  Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.

Bioinformatics

Product By Gene ID

138474

Alternate Names

210kDa 210kDa-like EC 2.7.11 EC 2.7.11.1 MGC134910 TAF(II)210 TAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor TAF1L TAF1-like RNA polymerase II, TATA box binding protein (TBP)-associated factor TAF2A2 TBP-associated factor 1-like TBP-associated factor 210 kDa TBP-associated factor RNA polymerase 1-like Transcription initiation factor TFIID 210 kDa subunit transcription initiation factor TFIID subunit 1-like

Research Areas for TAF1L

Find related products by research area and learn more about each of the different research areas below.

Protein Kinase